Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation

被引：1

作者：

Al Malki, Monzr M. ^{[1
]}

Vasu, Sumithira ^{[2
,3
]}

Modi, Dipenkumar ^{[4
]}

Perales, Miguel-Angel ^{[5
,6
]}

Ghoda, Lucy Y. ^{[7
,8
]}

Bui, Donna ^{[9
]}

Edavana, Vineetha ^{[10
]}

Lu, Emily ^{[10
]}

Kim, Sojung ^{[10
]}

Suarez, Lauren ^{[10
]}

Oelke, Mathias ^{[10
]}

Bednarik, Daniel ^{[10
]}

Knight, Robert D. ^{[11
]}

Varela, Juan C. ^{[12
,13
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol HCT, 1500 E Duarte Rd, Duarte, CA 91010 USA

[2] Ohio State Univ, Div Hematol, Dept Internal Med, Columbus, OH USA

[3] Comprehens Canc Ctr Columbus, Div Hematol, Dept Internal Med, Columbus, OH USA

[4] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Blood & Marrow Stem Cell Transplant Program, Detroit, MI USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA

[7] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, 1500 E Duarte Rd, Duarte, CA 91010 USA

[8] City Hope Natl Med Ctr, Beckman Res Inst, Dept Hematol Malignancies Translat Sci, Gehr Family Ctr Leukemia Res, Duarte, CA USA

[9] City Hope Natl Med Ctr, Duarte, CA USA

[10] NexImmune Inc, Gaithersburg, MD USA

[11] NexImmune Inc, Berkeley Hts, NJ USA

[12] Florida Hosp, Blood & Marrow Transplant Ctr, Winter Pk, FL USA

[13] Advent Hlth, Blood & Marrow Transplant Program, Orlando, FL USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152419

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4819

引用

页数：5

共 50 条

[1] Preliminary analysis of a phase 1/2 study of NEXI-001 donor-derived multi-antigen-specific CD8+ T-cells for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT).
Al Malki, Monzr
Vasu, Sumithira
Modi, Dipenkumar
Perales, Miguel-Angel
Bui, Donna
Edavana, Vineetha
Kim, Sojung
Suarez, Lauren
Oelke, Mathias
Bednarik, Dan
Knight, Robert D.
Varela, Juan Carlos
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT)
Al Malki, Monzr M.
Vasu, Sumithira
Modi, Dipenkumar
Afonso-Smith, Suzanne D.
Kim, Sojung
Lu, Emily
Marcucci, Guido
Oelke, Mathias
Knight, Robert D.
Varela, Juan Carlos
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] Initial Characterization of Nexi-001, a Donor-Derived T-Cell Product, for the Treatment AML Patients That Have Relapsed after Allogeneic Hematopoietic Stem Cell Transplant
Varela, Juan Carlos
Kim, Sojung
Knight, Robert D.
Lu, Emily
Wang, Ruipeng
Al Malki, Monzr M.
BLOOD, 2022, 140 : 4521 - 4521
[4] Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses
Al Malki, Monzr M.
Perales, Miguel-Angel
Modi, Md Dipenkumar
Vasu, Sumithira
Nelson, Megan
Bui, Donna
Kim, Sojung
Wang, Ruipeng
Lu, Emily
Oelke, Mathias
Myint, Han
Varela, Juan C.
BLOOD, 2020, 136
[5] Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation
Shah, Nirali N.
Azzi, Jacques
Cooper, Brenda W.
Deol, Abhinav
DiPersio, John
Koura, Divya
McClune, Brian
Muffly, Lori S.
Mushtaq, Muhammad Umair
Narayan, Rupa
Suh, Hyung Chan
Yanik, Gregory
Nath, Sritama
Whangbo, Jennifer
Koehne, Guenther
BLOOD, 2023, 142
[6] Allogeneic Donor-Derived Myeloid Antigen Directed CAR-T Cells - for Relapsed/Refractory Acute Myeloid Leukemia in Children after Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Cases
Shelikhova, Larisa
Rakhteenko, Arina
Molostova, Olga
Kurnikova, Elena
Ukrainskaya, V
Muzalevsky, Yakov
Pershin, Dmitry
Popov, Alexander
Kulakovskaya, Elena
Baidildina, Dina
Stepanov, Alexey
Osipova, Elena
Novichkova, Galina
Maschan, Alexey
Maschan, Michael
BLOOD, 2022, 140 : 4600 - 4601
[7] DONOR-DERIVED CAR-T CELLS FOR THE TREATMENT OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Deng, Lei
Yu, Xiaolin
Song, Xiaocheng
Guan, Rui
Shao, Yan
Li, Wenjun
Zhou, Fang
BONE MARROW TRANSPLANTATION, 2024, 59 : 47 - 48
[8] DONOR-DERIVED CLL-1 CHIMERIC ANTIGEN RECEPTOR T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BRIDGING TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT UPDATE
Miao, Xiaojuan
Shuai, Yanrong
Han, Ying
Liu, Yilan
Zhang, Nan
Yao, Hao
Wang, Xiao
He, Guangcui
Chen, Dan
Fan, Fangyi
Chang, Alex H.
Su, Yi
Yi, Hai
BONE MARROW TRANSPLANTATION, 2024, 59 : 219 - 219
[9] Phase 1/2 Study of Nexi-002 Autologous MultiAntigen-Specific CD8+T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma
Knight, Robert D.
Htut, Myo
Varela, Juan C.
Kin, Andrew
Edavana, Vineetha
Lu, Emily
Kim, Sojung
Suarez, Lauren
Oelke, Mathias
Bednarik, Daniel
BLOOD, 2021, 138
[10] Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
马润芝
China Medical Abstracts(Internal Medicine), 2021, 38 (04) : 228 - 229

← 1 2 3 4 5 →